Summary
4F-MABP is a little-studied fluorinated analogue of buphedrone first identified on the European NPS market in 2014. Animal data and seizure analyses show it acts as a dopamine and norepinephrine reuptake inhibitor comparable in potency to flephedrone. Human reports are scarce; effects resemble other short-acting cathinones with rapid onset euphoria, strong urge to redose, and an uncomfortable crash. Because no pharmacological or toxicological studies in humans exist, dosing should start low. Users have reported pronounced peripheral vasoconstriction and tachycardia.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Oral | 15-30 min | 30-45 min | 1-2 hrs | 1-2 hrs | 2-6 hrs |
| Insufflated | 2-5 min | 10-20 min | 30-90 min | 30-60 min | 2-6 hrs |
Tolerance
Build-up
develops rapidly, often within a single session; compulsive redosing common
Reset
a few days for acute tolerance
Effects
Positive
- Stimulation
Negative
- Vasoconstriction
- Temperature regulation suppression
- Teeth grinding
- Jaw clenching
- Increased heart rate
- Increased blood pressure
- Insomnia
- Nausea
- Sedation
Positive
- Euphoria
- Focus enhancement
- Motivation enhancement
- Increased sociability
- Empathy enhancement
- Cognitive euphoria
Negative
- Anxiety
- Compulsive redosing
- Talkativeness
- Time distortion
Positive
- Music appreciation enhancement
- Increased libido
- Increased music appreciation
- Color enhancement
- Tactile enhancement
Negative
- Appetite suppression
- Dehydration
- Light sensitivity
- Disinhibition
- Dulled perception